Palliative Care in Respiratory System Malignancies: A Clinically Verified Review

 Palliative Care in Respiratory System Malignancies: A Clinically Verified Review

Author: Dr. Shekhar and team Doctor's forum for all 🏥 

Disclaimer: This article is for educational and clinical reference only. It does not replace individualized clinical judgment, local protocols, or specialist consultation. Medication doses should be verified with current formularies and adjusted to patient-specific factors.

Abstract

Respiratory system malignancies—principally primary lung cancers, malignant pleural mesothelioma, pulmonary neuroendocrine tumours, and metastatic disease involving the lungs and pleura—carry a high symptom burden and often a limited prognosis. Palliative care in these conditions is not limited to terminal care; it is an active, concurrent layer of support that begins at diagnosis and continues through disease progression and end of life. This article reviews the major pathological conditions affecting the respiratory system and provides a detailed, clinically verified approach to palliative symptom management, including dyspnoea, cough, haemoptysis, pain, malignant pleural effusion, superior vena cava obstruction, central airway obstruction, brain and bone metastases, fatigue, cachexia, and psychological distress.

1. Introduction

Palliative care is defined by the World Health Organization as an approach that improves quality of life for patients and families facing life-threatening illness through early identification and impeccable assessment and treatment of pain and other physical, psychosocial, and spiritual problems [1].

Respiratory cancers are a leading cause of cancer-related death worldwide. Lung cancer alone accounts for approximately 1.8 million deaths annually [2]. Patients with advanced respiratory malignancies frequently suffer from breathlessness, cough, haemoptysis, chest pain, fatigue, anorexia, and psychological distress. Early integration of palliative care into oncology has been shown to improve quality of life, mood, and even survival in patients with metastatic non-small cell lung cancer (NSCLC) [3].

This article outlines a condition-specific palliative approach for the major malignant pathologies of the respiratory system.

2. General Principles of Palliative Care in Respiratory Malignancies

1. Concurrent palliative care should be integrated with disease-directed therapy from diagnosis [3,4].

2. Interdisciplinary teamwork is essential: oncologist, palliative care physician, respiratory physician, interventional radiologist, pain specialist, nurse, psychologist, social worker, and chaplain.

3. Symptom-driven management should prioritise patient-reported outcomes and quality of life, not only tumour response.

4. Advance care planning should begin early, including preferences for ventilation, cardiopulmonary resuscitation, hospitalisation, and place of death.

5. Regular reassessment of symptoms, goals, and treatment burden is mandatory.

3. Major Pathological Conditions and Palliative Approaches

3.1 Non-Small Cell Lung Cancer (NSCLC)

NSCLC accounts for about 85% of lung cancers and includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Clinical presentation depends on tumour location and stage. Common symptoms include cough, dyspnoea, haemoptysis, chest pain, weight loss, hoarseness, and superior vena cava syndrome. Metastatic disease often affects brain, bone, liver, and adrenal glands.

Palliative approach in NSCLC:

· Dyspnoea: Treat reversible causes such as pleural effusion, anaemia, infection, pulmonary embolism, or airway obstruction. Non-pharmacological measures include a fan, cool air, pursed-lip breathing, and energy conservation. Low-dose oral or parenteral opioids are first-line for refractory dyspnoea [5]. Oxygen is indicated only if the patient is hypoxaemic (SpO₂ ≤ 90%). Benzodiazepines may be used cautiously for associated anxiety but are not first-line for dyspnoea alone.

· Cough: Evaluate for infection, postnasal drip, gastro-oesophageal reflux, or endobronchial tumour. Antitussives such as codeine or morphine are effective. Corticosteroids may reduce tumour-related airway inflammation. Endobronchial therapies, including laser, cryotherapy, or stent placement, can relieve obstructing lesions.

· Haemoptysis: Palliative thoracic radiotherapy is effective for symptomatic control. Bronchial artery embolisation is the procedure of choice for massive haemoptysis. In terminal massive haemoptysis, comfort measures include dark towels, sedation with midazolam, and family preparation.

· Pain: Chest wall pain, Pancoast tumour, rib metastases, and neuropathic pain are common. Use the WHO analgesic ladder. Opioids remain the mainstay. Adjuvants such as gabapentin or amitriptyline help neuropathic pain. Palliative radiotherapy provides excellent relief for localised bone or chest wall pain. Intercostal nerve blocks or epidural analgesia may be required for refractory pain.

· Malignant pleural effusion: See section 3.6.

· Brain metastases: Dexamethasone 8–16 mg daily reduces peritumoural oedema. Whole-brain or stereotactic radiotherapy may improve neurological symptoms. Anticonvulsants are indicated only if seizures occur.

· Bone metastases: Palliative radiotherapy (e.g., 8 Gy single fraction) is effective. Bisphosphonates or denosumab reduce skeletal-related events.

· Fatigue and cachexia: Corticosteroids such as dexamethasone 4–8 mg daily can improve appetite and energy for short periods. Megestrol acetate may improve appetite but increases thromboembolic risk. Nutritional support, physiotherapy, and psychological counselling are important.

3.2 Small Cell Lung Cancer (SCLC)

SCLC is a rapidly growing neuroendocrine tumour, usually centrally located, with early haematogenous spread. It is strongly associated with smoking. Patients commonly present with cough, dyspnoea, weight loss, superior vena cava obstruction, and paraneoplastic syndromes such as SIADH, ectopic ACTH syndrome, and Lambert–Eaton myasthenic syndrome.

Palliative approach in SCLC:

· Superior vena cava obstruction: Dexamethasone 8–16 mg daily initially, urgent radiotherapy, chemotherapy, or endovascular stenting. Symptoms of facial swelling, headache, and dyspnoea can improve rapidly with stenting [6].

· Brain metastases: Very common in SCLC. Dexamethasone and whole-brain radiotherapy provide symptom relief. In patients with poor performance status, palliative care alone may be appropriate.

· Paraneoplastic syndromes: Treat underlying cancer with chemotherapy if feasible. Symptomatic management includes fluid restriction and demeclocycline for SIADH; ketoconazole or metyrapone for ectopic ACTH; and supportive care for myasthenic symptoms.

· Dyspnoea and haemoptysis: Similar palliative approach as for NSCLC. Central airway obstruction may require bronchoscopic intervention.

· Chemotherapy: Platinum-based chemotherapy often provides rapid symptom relief even in advanced disease. However, in patients with poor performance status or significant comorbidities, the burden of chemotherapy should be discussed openly.

· End-of-life care: SCLC has a short illness trajectory. Advance care planning should be prioritised early after diagnosis.

3.3 Malignant Pleural Mesothelioma

Mesothelioma arises from pleural mesothelial cells and is strongly linked to asbestos exposure. The disease causes progressive pleural thickening, chest wall pain, dyspnoea, cough, weight loss, and recurrent pleural effusion.

Palliative approach in mesothelioma:

· Pleural effusion: Repeated thoracentesis is not recommended as a long-term strategy. Talc pleurodesis or insertion of an indwelling pleural catheter provides effective palliation of dyspnoea [7]. Indwelling catheters allow home drainage and may be preferred if the lung is trapped.

· Chest wall pain: Often severe and difficult to control. Use regular opioids combined with adjuvants. Gabapentin or pregabalin helps neuropathic pain. Radiotherapy can palliate localised chest wall pain or tumour nodules, though its routine prophylactic use after chest drain is not recommended. In refractory cases, cordotomy or intrathecal analgesia may be considered.

· Dyspnoea: Due to pleural restriction, effusion, and respiratory muscle dysfunction. Opioids remain essential. Oxygen may provide comfort even if hypoxaemia is mild. A fan and breathing techniques help.

· Palliative chemotherapy/immunotherapy: Pemetrexed plus platinum or immunotherapy may improve symptoms and survival in selected patients. However, the decision should balance benefit against toxicity.

· Psychological support: Mesothelioma has a poor prognosis and often carries anger and compensation-related distress. Psychological and spiritual care is essential.

3.4 Pulmonary Neuroendocrine Tumours and Carcinoid Tumours

Pulmonary carcinoid and other neuroendocrine tumours may present with obstructive pneumonia, cough, haemoptysis, and wheezing. Carcinoid syndrome with flushing, diarrhoea, and wheezing is rare unless liver metastases are present.

Palliative approach:

· Airway obstruction: Bronchoscopic debulking with laser, argon plasma coagulation, or cryotherapy can relieve obstruction and improve dyspnoea.

· Carcinoid syndrome: Somatostatin analogues such as octreotide or lanreotide reduce flushing and diarrhoea. Ensure adequate hydration and electrolyte replacement.

· Haemoptysis: Bronchoscopic interventions or palliative radiotherapy may be needed.

· Pain and dyspnoea: Standard opioid and non-pharmacological measures apply.

3.5 Central Airway Obstruction

Central airway obstruction may be caused by primary bronchogenic carcinoma, metastatic disease, or mediastinal lymphadenopathy. It causes severe dyspnoea, stridor, cough, haemoptysis, and post-obstructive pneumonia.

Palliative approach:

· Bronchoscopic interventions: Laser photoresection, argon plasma coagulation, cryotherapy, and balloon dilatation can rapidly improve airway patency.

· Tracheobronchial stents: Silicone or self-expanding metallic stents maintain airway patency. Stenting is particularly useful for extrinsic compression.

· Brachytherapy or external beam radiotherapy: Provide more gradual symptom relief but are effective for endobronchial tumour.

· Oxygen, opioids, and sedation: In patients not suitable for interventions, opioids and low-dose benzodiazepines manage dyspnoea and anxiety. A clear ceiling of care should be documented.

3.6 Malignant Pleural Effusion

Malignant pleural effusion is a frequent complication of lung cancer, breast cancer, lymphoma, and mesothelioma. It causes progressive dyspnoea, cough, and chest discomfort.

Palliative approach:

· Large-volume thoracentesis provides immediate symptomatic relief and helps assess lung re-expansion.

· Talc pleurodesis is effective for recurrent effusion when the lung re-expands.

· Indwelling pleural catheter is preferred when the lung is trapped or pleurodesis fails. It allows intermittent home drainage and improves quality of life [7].

· Symptom control: Opioids for dyspnoea and pain. Diuretics are not routinely indicated unless there is concurrent heart failure or hypoalbuminaemia.

· Advance planning: Recurrent effusions indicate advanced disease. Discussions about goals of care should be held.

3.7 Superior Vena Cava Syndrome (SVCS)

SVCS occurs due to extrinsic compression or thrombosis of the superior vena cava, most commonly from lung cancer, especially SCLC.

Palliative approach:

· Steroids: Dexamethasone 8–16 mg daily may reduce tumour oedema, though evidence is limited [6].

· Radiotherapy: Urgent palliative radiotherapy is often effective, especially in NSCLC.

· Chemotherapy: In chemo-sensitive tumours such as SCLC or lymphoma, chemotherapy may relieve obstruction rapidly.

· Endovascular stenting: Provides rapid relief of facial swelling, headache, and dyspnoea and is particularly useful for severe symptoms or recurrent obstruction.

· Anticoagulation: If thrombosis is present, anticoagulation may be considered.

· Supportive care: Elevation of the head, oxygen, and opioids for dyspnoea.

3.8 Haemoptysis

Haemoptysis is a distressing and potentially life-threatening symptom in respiratory malignancies.

Palliative approach:

· Mild-to-moderate haemoptysis: Palliative radiotherapy, bronchoscopic interventions, or tranexamic acid may help.

· Massive haemoptysis: Bronchial artery embolisation is the first-line intervention in patients who are candidates for active management. In terminal patients, immediate comfort care is appropriate.

· Terminal haemoptysis protocol: Have a clear plan in place. Use dark towels to reduce visual distress, position the patient on the affected side, administer intravenous or subcutaneous midazolam and opioids, and ensure family support.

· Communication: Discuss the possibility of massive haemoptysis and preferences in advance, especially in patients with large central tumours.

3.9 Pain in Respiratory Malignancies

Chest wall pain, rib metastases, Pancoast tumour, post-thoracotomy pain, and neuropathic pain are common.

Palliative approach:

· WHO analgesic ladder: Start with non-opioids (paracetamol, NSAIDs), then weak opioids, then strong opioids (morphine, oxycodone, fentanyl).

· Adjuvants: Gabapentin, pregabalin, amitriptyline, or duloxetine for neuropathic pain. Corticosteroids reduce pain from bone metastases, nerve compression, and brain metastases.

· Radiotherapy: Single-fraction 8 Gy is as effective as multi-fraction regimens for bone pain.

· Interventional pain management: Intercostal nerve blocks, paravertebral blocks, epidural analgesia, or intrathecal drug delivery for refractory pain.

· Non-pharmacological: Physiotherapy, TENS, heat/cold application, cognitive behavioural therapy, and relaxation techniques.

3.10 Dyspnoea

Dyspnoea is one of the most distressing symptoms in advanced respiratory cancer.

Palliative approach:

· Treat reversible causes: Pleural effusion, anaemia, infection, airway obstruction, pulmonary embolism, and superior vena cava obstruction.

· Non-pharmacological interventions: Fan therapy, cool air, open window, relaxation, pursed-lip breathing, and positioning.

· Opioids: Low-dose oral morphine (e.g., 2.5–5 mg every 4 hours as needed) or subcutaneous morphine improves dyspnoea without causing significant respiratory depression [5].

· Oxygen: Only if hypoxaemic (SpO₂ ≤ 90%). In non-hypoxaemic patients, oxygen is no better than air.

· Benzodiazepines: Used for associated anxiety or panic, but not first-line for isolated dyspnoea.

· Palliative sedation: In refractory dyspnoea with severe distress, continuous subcutaneous midazolam may be indicated at end of life.

3.11 Cough

Chronic cough affects up to 80% of lung cancer patients.

Palliative approach:

· Identify and treat reversible causes: Infection, postnasal drip, gastro-oesophageal reflux, drug-induced cough (e.g., ACE inhibitors), or secretions.

· Antitussives: Codeine, morphine, or dextromethorphan are effective. Sodium cromoglycate or benzonatate may be tried.

· Corticosteroids: Reduce tumour-related airway inflammation and oedema.

· Bronchoscopic interventions: Laser, stent, or brachytherapy for endobronchial tumour.

· Non-pharmacological: Steam inhalation, honey, and cough suppression techniques.

3.12 Fatigue, Anorexia, and Cachexia

These are nearly universal in advanced respiratory cancer.

Palliative approach:

· Corticosteroids: Dexamethasone 4–8 mg daily can improve appetite, energy, and wellbeing for short periods.

· Megestrol acetate: May improve appetite but increases thromboembolic risk; use cautiously.

· Address reversible causes: Anaemia, infection, depression, hypothyroidism, dehydration, and medications.

· Nutritional counselling: Small, frequent meals; oral nutritional supplements; avoid strict dietary restrictions.

· Exercise and physiotherapy: Graded exercise improves fatigue and functional capacity.

· Psychosocial support: Cognitive behavioural therapy and mindfulness may help.

3.13 Brain Metastases

Brain metastases are common in lung cancer and SCLC.

Palliative approach:

· Corticosteroids: Dexamethasone 8–16 mg daily reduces peritumoural oedema and neurological symptoms. Taper once radiotherapy is completed.

· Radiotherapy: Whole-brain radiotherapy or stereotactic radiosurgery may improve neurological function and quality of life.

· Anticonvulsants: Only if seizures occur; prophylactic use is not recommended.

· Symptom control: Analgesics for headache, antiemetics for nausea, and psychological support for cognitive and personality changes.

· End-of-life care: Progressive brain metastases often lead to reduced consciousness, dysphagia, and terminal agitation. Use subcutaneous medications as needed.

3.14 Psychological and Spiritual Distress

Patients with respiratory cancer frequently experience anxiety, depression, breathlessness-related panic, social isolation, and existential distress.

Palliative approach:

· Routine screening for anxiety and depression using validated tools such as the Hospital Anxiety and Depression Scale (HADS).

· Pharmacotherapy: SSRIs such as sertraline or citalopram are first-line for depression and anxiety.

· Psychological therapies: Cognitive behavioural therapy, counselling, and relaxation techniques.

· Spiritual care: Chaplaincy, meaning-making, legacy work, and cultural rituals.

· Family support: Caregiver burden is high; offer respite and bereavement support.

4. Advance Care Planning and End-of-Life Care

Advance care planning is crucial in respiratory malignancies due to the unpredictable trajectory and risk of sudden deterioration.

Key elements:

· Discuss goals of care, values, and preferences early.

· Document preferences for cardiopulmonary resuscitation, mechanical ventilation, and intensive care.

· Discuss preferred place of care and death.

· Review and stop non-essential medications, including disease-directed therapy, in the terminal phase.

· Ensure a plan for terminal haemoptysis, airway obstruction, and dyspnoea crisis.

End-of-life symptom control:

· Pain: Continuous subcutaneous morphine or diamorphine via syringe driver.

· Dyspnoea: Morphine 2.5–5 mg subcutaneously every 4 hours as needed; midazolam for associated anxiety.

· Respiratory secretions: Glycopyrronium 0.2–0.4 mg subcutaneously every 6 hours as needed.

· Agitation: Midazolam 2.5–5 mg subcutaneously as needed.

· Nausea and vomiting: Haloperidol 0.5–1.5 mg subcutaneously every 8 hours as needed.

· Comfort measures: Mouth care, skin care, bladder and bowel care, and a quiet environment.

5. Conclusion

Palliative care in respiratory system malignancies is an essential and complex discipline that requires a systematic, symptom-driven, and patient-centred approach. The major pathological conditions—non-small cell lung cancer, small cell lung cancer, malignant pleural mesothelioma, pulmonary neuroendocrine tumours, malignant pleural effusion, central airway obstruction, superior vena cava syndrome, and metastatic complications—each present distinct challenges. Early integration of palliative care improves quality of life and should be the standard of care. Effective management includes meticulous symptom control, interventional procedures where appropriate, psychological and spiritual support, and compassionate end-of-life care.

References

1. World Health Organization. Palliative Care. 5 August 2020. https://www.who.int/news-room/fact-sheets/detail/palliative-care

2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

3. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742. doi:10.1056/NEJMoa1000678

4. Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into standard oncology care: ASCO clinical practice guideline update. J Clin Oncol.2017;35(1):96-112